Her Crohn’s Biologic Was Denied Three Times, Then Approved

In March 2023, Elena opened a notebook and wrote down the sentence she could not get past: the requested biologic was not medically necessary. Under it, she wrote the month, the insurer’s stated reason and the date range for the next appeal.

Elena is a composite, but the problem is familiar. She had lived with Crohn’s disease for eight years, and the treatment that had kept her symptoms manageable was no longer doing that. Over six weeks she lost 11 pounds, sometimes made ten bathroom trips a day and stopped commuting because she could not count on getting through the drive.

Her specialist wanted to move her to a different biologic, a targeted therapy intended to interrupt part of the inflammatory process. The office submitted a prior authorization request and marked it urgent. Three days later, the denial appeared in the patient portal.

The words not medically necessary sounded like a medical judgment. They were really an insurance judgment about whether the paperwork matched the plan’s coverage policy, which is a different thing and a distinction insurers rarely make plain.

The first denial was about the insurer’s sequence

The denial said Elena had not completed the plan’s preferred treatment sequence. In plain English, the insurer wanted evidence that she had tried other covered drugs first, or that there was a documented reason she could not use them, before it would pay for the biologic her specialist selected.

That requirement is usually called step therapy. The jargon makes it sound clinical. What it hides is that the insurer, not the treating specialist, has placed treatments in an order that may reflect negotiated prices and coverage policy as well as medical evidence.

Elena had already used an older medication and a previous biologic. One stopped working. The other had caused problems recorded in her chart. Her specialist believed the proposed therapy fit her current disease pattern, but the first submission contained visit notes rather than a clear explanation of how those years of treatment lined up with each part of the insurer’s rule.

That gap mattered. The records showed what had happened to her, yet they did not answer the insurer in the format its reviewers were applying.

The specialist’s office requested an urgent internal appeal. A clinician from the insurer also spoke with Elena’s specialist, a step often called a peer-to-peer review. The name suggests two doctors working through a medical disagreement. In practice, that conversation did not replace the written appeal, and it did not guarantee that the insurer’s reviewing clinician had the same specialty or authority to change the decision.

Five days after the first denial, the appeal was rejected. The insurer still said the record did not establish that Elena met its coverage criteria.

She added a second line to the notebook. Beside it, she wrote what had been sent: recent clinic notes and the specialist’s appeal. The page was becoming a phone log, but its useful part was not the count of calls. It showed which evidence had reached which review level, something neither the portal nor the denial letters displayed in one place.

The medical record had to answer an insurance rule

By then Elena was eating less because meals often meant more pain and urgency. Her specialist was managing the flare while the coverage dispute continued, but the proposed biologic remained out of reach. The denial process treated that delay as administration. Her body did not.

For the next appeal, the specialist’s office pulled older records that showed when prior treatments started and why they ended. Elena supplied pharmacy history that covered a gap in the chart. Her specialist submitted another explanation, marked urgent, connecting those records to the insurer’s policy and describing why further delay carried medical risk for her.

This was the consequential change. The first packet proved that Elena had Crohn’s disease and was unwell. The next one addressed the insurer’s actual objection, which was whether her treatment history satisfied the plan’s required sequence.

Eight days later, the second internal appeal was denied.

The new notice focused on one preferred therapy Elena had not used. Her specialist had explained why that option was not appropriate in her case, but the insurer upheld its position. The letter also said the plan’s internal appeal levels were exhausted, bureaucratic language meaning the insurer was finished reviewing its own decision.

Elena wrote a third denial in the notebook. Then she drew a line under it.

At that point, she had been fighting for coverage for 16 days while actively experiencing the flare. She had assumed that more records would produce a different answer, but the internal reviewers were still applying the same policy from inside the same insurance system. The next available route placed the dispute before someone outside it.

External review changed who decided

Elena requested an external review, using the instructions attached to the final denial. Her specialist completed the clinical section and marked the case urgent. The packet included the denial notices, treatment history and recent evidence of the flare, with the specialist explaining how delay could affect her health.

An external review is not another customer-service reconsideration. For eligible plans, an independent reviewer examines whether the insurer’s decision follows the plan terms and applicable medical standards. The route differs by state and type of health plan, which is why Elena followed the appeal rights printed on her own notice rather than assuming every insurance process worked the same way.

The urgent designation also had a specific purpose. Federal external-review rules for eligible plans require an expedited decision as quickly as the medical condition demands and no later than 72 hours after the request is received, although state systems and certain employer plans can follow different routes.

Elena’s independent reviewer reversed the denial within that window. The written decision found that the requested biologic was medically necessary under the circumstances documented by her specialist. The insurer then authorized coverage for six months.

The phrase was almost insulting in reverse. Nothing about Elena’s condition had changed between the third denial and the approval. What changed was the reviewer and the way the evidence was tied to the coverage dispute.

Approval did not put medication in her body that day. The specialist’s office still had to coordinate with the insurer and the infusion center, and Elena waited another nine days for treatment to begin. She kept calling because the portal showed the authorization before the scheduling system reflected it.

The notebook stayed open on her table. On one page were three denials over 16 days. On the next was the external-review decision, followed by the month of her first infusion.

What worked in her case

Elena’s appeal was not won by finding a forceful phrase or reaching a better customer-service representative. Her experience turned on two things: the record finally addressed the precise coverage rule behind the denial, and an independent reviewer evaluated the dispute after the insurer’s internal process was exhausted.

The notebook helped her keep those pieces straight while she was sick. She used it to track the stated reason for each denial and whether the next submission contained evidence that answered that reason, rather than recording every conversation as if persistence alone could overturn a policy.

Her specialist’s participation mattered more than the volume of paperwork. The successful packet did not merely repeat that the biologic was needed. It connected her prior treatment history and the active flare to the insurer’s objection, then explained why waiting through the standard review period posed a risk in her situation.

That is what worked for Elena. It was one person’s route through one plan, during one flare, and the approval lasted six months rather than settling the coverage question forever.

Questions people ask

Why can an insurer call a biologic not medically necessary?

In Elena’s case, the phrase meant the original submission did not satisfy the plan’s coverage policy, including its preferred treatment sequence. It did not mean her specialist thought the therapy lacked medical value. The denial compressed a dispute about documentation and insurance rules into language that sounded like a clinical verdict.

Can a prior authorization appeal be expedited during a flare?

Elena’s specialist marked both the internal appeal and external-review request urgent because delay could affect her health. The insurer still denied the internal appeals. The independent review moved under an expedited timeline, but eligibility and deadlines can vary by plan type, state process and the circumstances described in the medical record.

What made the external review different?

The external reviewer was independent of the insurer and considered the treatment history alongside the plan’s stated reason for denial. Elena had also exhausted the insurer’s internal levels by then. The outside decision did not erase the earlier denials; it reversed the coverage outcome for the requested biologic.

Did approval mean the biologic started right away?

No. Elena waited another nine days while the specialist’s office, insurer and infusion center completed their parts. The portal displayed approval before scheduling caught up. After the first infusion was booked, she wrote the month beside the overturned denial in her notebook.